Wick Capital Partners LLC Acquires New Stake in IQVIA Holdings Inc. $IQV

Wick Capital Partners LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, Holdings Channel reports. The firm bought 3,272 shares of the medical research company’s stock, valued at approximately $738,000.

A number of other institutional investors have also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the 4th quarter worth about $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA during the fourth quarter worth about $27,000. CrossGen Wealth LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $28,000. Finally, Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA in the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $168.14 on Friday. The company has a 50 day moving average of $173.72 and a 200 day moving average of $191.84. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $28.06 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.46 and a beta of 1.21. IQVIA Holdings Inc. has a 12 month low of $153.01 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the company posted $2.70 EPS. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of brokerages recently commented on IQV. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday. HSBC set a $210.00 price target on IQVIA in a report on Wednesday, June 3rd. Finally, Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.